<DOC>
	<DOCNO>NCT00150254</DOCNO>
	<brief_summary>The purpose study measure safety efficacy four dosing strategy CP-526,555 12 week compare placebo smoke cessation . Post-treatment follow-up smoking status one year randomization perform non-treatment extension Protocol A3051018</brief_summary>
	<brief_title>12 Week Evaluation Safety Efficacy 4 Dosing Strategies CP-526,555 Placebo Smoking Cessation .</brief_title>
	<detailed_description />
	<mesh_term>Varenicline</mesh_term>
	<criteria>Subjects must smoke average least ten cigarette per day past year Subjects must period abstinence great three month past year Subjects history clinically significant cardiovascular disease Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>